Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk CEO Maziar Mike Doustdar (left) and Eli Lilly CEO David Ricks (Viktoria Nikolova for Endpoints News) August 4, 2026 11:00 AM EDTUpdated 11:19 AM PharmaIn FocusGLP-1 drugs No­vo vs. Lil­ly: Q2's car­diometa­bol­ic grudge match Kyle LaHucik Biotech Correspondent Elizabeth Cairns Senior biopharma journalist For years, No­vo Nordisk and Eli Lil­ly have dom­i­nat­ed the con­ver­sa­tion sur­round­ing obe­si­ty med­i­cines as the du­op­oly com­petes to lead the largest phar­ma­ceu­ti­cal cat­e­go­ry in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER